Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study to Evaluate the Efficacy, Safety and Tolerability of Single Doses of BCX7353 as an Acute Attack Treatment in Subjects With Hereditary Angioedema

NCT03240133 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT03240133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03240133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study to Evaluate the Efficacy, Safety and Tolerability of Single Doses of BCX7353 as an Acute Attack Treatment in Subjects With Hereditary Angioedema
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2017
Completion date
January 29, 2019
Enrollment
58 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)